Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146536 · ClinicalTrials.gov registry record
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 78
- Enrollment target
NCT00146536: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT00146536 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00146536 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2004-11 |
| Est. Completion | 2012-11 |
What the finished NCT00146536 record still lists
NCT00146536 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00146536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00146536 about?
NCT00146536 is a clinical study titled "Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy". The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
What is the current status of trial NCT00146536?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2004-11. Estimated completion is 2012-11.
Who is sponsoring clinical trial NCT00146536?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia